[go: up one dir, main page]

TR201911328T4 - İlaç, organik çözücü, lipofilik merhem bazı ve tozun harmanlanmasıyla elde edilen yapıştırıcı preparasyon bileşimi. - Google Patents

İlaç, organik çözücü, lipofilik merhem bazı ve tozun harmanlanmasıyla elde edilen yapıştırıcı preparasyon bileşimi. Download PDF

Info

Publication number
TR201911328T4
TR201911328T4 TR2019/11328T TR201911328T TR201911328T4 TR 201911328 T4 TR201911328 T4 TR 201911328T4 TR 2019/11328 T TR2019/11328 T TR 2019/11328T TR 201911328 T TR201911328 T TR 201911328T TR 201911328 T4 TR201911328 T4 TR 201911328T4
Authority
TR
Turkey
Prior art keywords
drug
organic solvent
patch preparation
powder
composition obtained
Prior art date
Application number
TR2019/11328T
Other languages
English (en)
Inventor
Hamamoto Hidetoshi
Yamanaka Katsuhiro
Tanimoto Takahiro
Original Assignee
Medrx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49768781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201911328(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medrx Co Ltd filed Critical Medrx Co Ltd
Publication of TR201911328T4 publication Critical patent/TR201911328T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluşun amacı, bir sulu olmayan yama preparasyonuna yönelik olarak, bir ilacı sürekli olarak salabilen mükemmel yapışabilirliğine sahip bir bileşim sağlamaktır. Mevcut buluşun yama preparasyonu, bir toz içeriğinin (bir dolgu maddesi veya benzeri) ilavesiyle yama preparasyonunun yapışabilirliğini ve bir ilacın salınım özelliğini iyileştirebilir. Sonuç olarak, bant preparasyonlarının yapışabilirliğinin uzun süreli tutulması, bir iyileştirilmiş deri içi emilebilirliğine ve bir ilacın sürekli salınımına olanak sağlar. Bu toz içeriğini içeren bir bileşin bir yama preparasyonuna yönelik olarak kullanımı ile, bir ilacın tipine bakılmaksızın, bir ilaç, organik çözücüyü içeren bir ilaç çözeltisi hazırlamak üzere bir organik çözücü veya bir iyonik sıvı içinde çözündürülür, ilaç çözeltisi, mevcut buluşun sulu olmayan yama preparasyonuna dahil edilir ve bu sebeple iyileştirilmiş deri içi emilebilirliğe ve iyileştirilmiş sürekli salınıma sahip bir preparasyon hazırlanabilir.
TR2019/11328T 2012-06-20 2013-06-18 İlaç, organik çözücü, lipofilik merhem bazı ve tozun harmanlanmasıyla elde edilen yapıştırıcı preparasyon bileşimi. TR201911328T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012139215 2012-06-20

Publications (1)

Publication Number Publication Date
TR201911328T4 true TR201911328T4 (tr) 2019-08-21

Family

ID=49768781

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/11328T TR201911328T4 (tr) 2012-06-20 2013-06-18 İlaç, organik çözücü, lipofilik merhem bazı ve tozun harmanlanmasıyla elde edilen yapıştırıcı preparasyon bileşimi.

Country Status (16)

Country Link
US (2) US10543275B2 (tr)
EP (1) EP2865376B2 (tr)
JP (1) JP6309892B2 (tr)
CN (3) CN104363900A (tr)
AU (1) AU2013278403B2 (tr)
BR (1) BR112014031701A2 (tr)
CA (1) CA2875454C (tr)
DK (1) DK2865376T4 (tr)
ES (1) ES2738303T5 (tr)
HU (1) HUE045479T2 (tr)
IN (1) IN2014DN10706A (tr)
PL (1) PL2865376T5 (tr)
PT (1) PT2865376T (tr)
SI (1) SI2865376T1 (tr)
TR (1) TR201911328T4 (tr)
WO (1) WO2013191187A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824883B1 (en) * 2013-09-11 2023-08-02 MEDRx Co., Ltd. Novel composition for plaster base material in tape preparation
CN103830206B (zh) * 2014-02-26 2016-08-31 上海现代药物制剂工程研究中心有限公司 阿戈美拉汀三维网状立体构型的透皮给药制剂及制备方法
EP3111935A4 (en) 2014-02-27 2017-03-15 Medrx Co., Ltd. Pramipexole-containing transdermal patch for treatment of neurodegenerative disease
WO2016109483A1 (en) * 2014-12-30 2016-07-07 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for agomelatine
WO2017037812A1 (ja) * 2015-08-29 2017-03-09 株式会社メドレックス 酸捕捉剤を含有する貼付製剤
US10016502B2 (en) 2015-08-29 2018-07-10 Medrx Co., Ltd Patch preparation containing an acid scavenger
CN107427509B (zh) * 2015-08-29 2021-06-15 美德阿利克斯株式会社 含有碱性药物和山梨酸的经皮吸收组成物
ES2957234T3 (es) * 2016-03-24 2024-01-15 Medrx Co Ltd Preparación de parche con características de prevención del uso incorrecto de sustancias
US20170273974A1 (en) 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
JP7143219B2 (ja) * 2016-11-09 2022-09-28 株式会社クラレ 粘着シート、絆創膏及びこれらの製造方法
US20220016061A1 (en) * 2018-10-04 2022-01-20 Medrx Co., Ltd. Preparation Stabilized by Means of Nonaqueous Solvent
US20240108578A1 (en) * 2021-02-12 2024-04-04 Medrx Co., Ltd. Composition in which absorbability of poorly absorbable drug is improved
JP7179212B1 (ja) 2022-05-02 2022-11-28 久光製薬株式会社 リドカイン含有貼付剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3144895B2 (ja) 1992-06-30 2001-03-12 積水化学工業株式会社 医療用粘着テープもしくはシート
JPH06145050A (ja) * 1992-11-11 1994-05-24 Sekisui Chem Co Ltd 貼付剤の製造方法
JPH07145047A (ja) 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 局所麻酔用経皮吸収テープ
JPH0827003A (ja) 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
JPH09169636A (ja) 1995-06-12 1997-06-30 Sekisui Chem Co Ltd 貼付剤
JPH09136834A (ja) 1995-11-14 1997-05-27 Sekisui Chem Co Ltd 経皮吸収貼付剤
JP4648518B2 (ja) * 2000-06-01 2011-03-09 帝國製薬株式会社 ４−ビフェニル酢酸含有貼付剤
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US6503532B1 (en) * 2001-04-13 2003-01-07 Murty Pharmaceuticals, Inc. Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof
JP4758101B2 (ja) * 2002-09-13 2011-08-24 久光製薬株式会社 貼付剤
EP1591110B1 (en) * 2003-01-22 2015-03-18 Senju Pharmaceutical Co., Ltd. Percutaneous absorption preparation for treating ophthalmic disease, use thereof and method for migration of ophthalmic remedy into topical tissue in eye
US8080261B2 (en) * 2004-09-30 2011-12-20 Teikoku Pharma Usa, Inc. 1-chloro-2,4-dinitrobenzene non-aqueous gel compositions and methods for using the same
US20090258063A1 (en) * 2006-09-11 2009-10-15 Sekisui Chemical Co., Ltd. Transdermal patch
EP2062576B1 (en) 2006-09-11 2012-02-01 Sekisui Chemical Co., Ltd. Adhesive preparation comprising desglymidodrine
US8623387B2 (en) * 2007-11-22 2014-01-07 Medrx Co., Ltd. External preparation composition comprising fatty acid-based ionic liquid as active ingredient
EP2258396B1 (en) 2008-03-03 2017-09-06 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable preparation
JP4822032B2 (ja) 2009-01-08 2011-11-24 タイヨーエレック株式会社 組合せ式遊技機
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
DE102009022915A1 (de) * 2009-05-27 2010-12-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit gesteuertem Wirkstofffluss
JP2011074035A (ja) * 2009-09-30 2011-04-14 Sekisui Medical Co Ltd 貼付剤

Also Published As

Publication number Publication date
PT2865376T (pt) 2019-08-26
DK2865376T3 (da) 2019-08-12
PL2865376T3 (pl) 2019-12-31
CN108553452A (zh) 2018-09-21
WO2013191187A1 (ja) 2013-12-27
SI2865376T1 (sl) 2019-11-29
US12016924B2 (en) 2024-06-25
HUE045479T2 (hu) 2019-12-30
EP2865376A1 (en) 2015-04-29
CN110693859A (zh) 2020-01-17
ES2738303T3 (es) 2020-01-21
AU2013278403B2 (en) 2018-02-01
CA2875454C (en) 2021-02-16
BR112014031701A2 (pt) 2017-06-27
EP2865376B2 (en) 2022-05-11
DK2865376T4 (da) 2022-07-18
JP6309892B2 (ja) 2018-04-11
JPWO2013191187A1 (ja) 2016-05-26
ES2738303T5 (es) 2022-09-12
AU2013278403A1 (en) 2015-01-22
EP2865376A4 (en) 2015-11-18
US10543275B2 (en) 2020-01-28
US20190388544A1 (en) 2019-12-26
EP2865376B1 (en) 2019-06-05
PL2865376T5 (pl) 2023-01-09
CN104363900A (zh) 2015-02-18
CA2875454A1 (en) 2013-12-27
IN2014DN10706A (tr) 2015-09-04
US20150174249A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
TR201911328T4 (tr) İlaç, organik çözücü, lipofilik merhem bazı ve tozun harmanlanmasıyla elde edilen yapıştırıcı preparasyon bileşimi.
CY1120521T1 (el) Παρασκευασμα προμειγματος δεξμεδετομιδινης
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
MX2023008779A (es) Adenovirus armado con un activador biespecifico de linfocitos t.
MX380805B (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipofílicos y métodos para prepararlos y usarlos.
CR20120634A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CL2010001475A1 (es) Compuestos derivados de ester boronato, inhibidores de proteasoma; composiciones farmaceuticas que los contienen; procedimiento de preparacion de la composición farmaceutica; utiles en el tratamiento de enfermedades proliferativas celulares, en particular cancer.
CO6670585A2 (es) Promotores de apotosis n-acilsufonamidas
EA201391059A1 (ru) Композиции для лечения рака и способы их применения
DOP2015000077A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
EA201390090A1 (ru) Дезинфицирующий и антисептический препарат, имеющий сниженное содержание йода
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
DOP2015000145A (es) NUEVOS DERIVADOS CARBAMATO DE CICLOHEXILO Y QUINUCLIDINILO QUE TIENEN ACTIVIDAD COMO AGONISTAS ß2 ADRENÉRGICOS Y COMO ANTAGONISTAS MUSCARÍNICOS M3
DOP2015000137A (es) Dispersión sólida de un modulador selectivo de los receptores de progesterona
CO7240370A2 (es) Forma farmaceútica para la liberación prolongada de sustancias activas
EA201590269A1 (ru) Трансдермальный препарат, содержащий ингибиторы cox
BR112013017570A2 (pt) compostos de pirazola como antagonistas de crth2
IN2014DN09830A (tr)
MX2023003000A (es) Formulaciones de liberacion modificada de viloxacina.
EA201390980A1 (ru) Лекарственный пластырь для улучшенного трансдермального проникновения диклофенака диэтиламмония
CY1122538T1 (el) Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση
MX359436B (es) Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol.
CL2014002115A1 (es) Solución oxidante que contiene una mezcla de oxidante disuelto para la preparacion de formulaciones de explosivos; formulacion de explosivos.
BR112014031556A2 (pt) derivados de bendamustina e compostos relacionados, e uso médico dos mesmos na terapia do câncer
TR201906107T4 (tr) Dotap klorürün stabil kristal modifikasyonlarının hazırlanması.